X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11279) 11279
Newsletter (404) 404
Book Chapter (48) 48
Newspaper Article (48) 48
Dissertation (19) 19
Magazine Article (13) 13
Publication (4) 4
Government Document (3) 3
Conference Proceeding (2) 2
Reference (2) 2
Streaming Video (2) 2
Book / eBook (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (10402) 10402
humans (7467) 7467
multiple myeloma (4056) 4056
oncology (3898) 3898
hematology (3202) 3202
male (3067) 3067
female (2992) 2992
multiple myeloma - drug therapy (2792) 2792
middle aged (2452) 2452
aged (2231) 2231
cancer (2045) 2045
apoptosis (1926) 1926
dexamethasone (1694) 1694
animals (1672) 1672
antineoplastic combined chemotherapy protocols - therapeutic use (1618) 1618
antineoplastic agents - therapeutic use (1614) 1614
treatment outcome (1593) 1593
adult (1591) 1591
boronic acids - therapeutic use (1534) 1534
pyrazines - therapeutic use (1523) 1523
boronic acids - pharmacology (1506) 1506
cell line, tumor (1490) 1490
pyrazines - pharmacology (1479) 1479
proteasome inhibitors (1453) 1453
therapy (1439) 1439
chemotherapy (1415) 1415
antineoplastic agents - pharmacology (1310) 1310
multiple-myeloma (1295) 1295
boronic acids - administration & dosage (1236) 1236
pyrazines - administration & dosage (1232) 1232
lenalidomide (1213) 1213
care and treatment (1199) 1199
survival (1159) 1159
research (1154) 1154
apoptosis - drug effects (1152) 1152
thalidomide (1123) 1123
multiple myeloma - pathology (1023) 1023
transplantation (1014) 1014
mice (990) 990
stem-cell transplantation (958) 958
aged, 80 and over (913) 913
prognosis (808) 808
drug therapy (806) 806
dexamethasone - administration & dosage (793) 793
expression (774) 774
thalidomide - analogs & derivatives (772) 772
analysis (741) 741
proteins (739) 739
multiple myeloma - therapy (721) 721
multiple myeloma - mortality (701) 701
pharmacology & pharmacy (694) 694
combination (688) 688
proteasome endopeptidase complex - metabolism (688) 688
proteasome inhibitor bortezomib (688) 688
proteasome (680) 680
boronic acids - adverse effects (675) 675
pyrazines - adverse effects (673) 673
nf-kappa-b (642) 642
cell biology (639) 639
activation (632) 632
thalidomide - administration & dosage (623) 623
stem cells (613) 613
health aspects (611) 611
proteasome inhibitor (610) 610
hemic and lymphatic diseases (601) 601
antineoplastic agents - adverse effects (590) 590
antineoplastic combined chemotherapy protocols - adverse effects (587) 587
recurrence (585) 585
cells (572) 572
patients (571) 571
myeloma (570) 570
medicine & public health (567) 567
antineoplastic agents - administration & dosage (547) 547
cell proliferation - drug effects (545) 545
dose-response relationship, drug (541) 541
hematology, oncology and palliative medicine (541) 541
retrospective studies (539) 539
biochemistry & molecular biology (534) 534
disease-free survival (533) 533
thalidomide - therapeutic use (532) 532
abridged index medicus (531) 531
melphalan (528) 528
bortezomib - therapeutic use (520) 520
proteasome inhibitors - pharmacology (519) 519
multiple myeloma - genetics (510) 510
drug synergism (508) 508
trial (505) 505
multiple myeloma - diagnosis (492) 492
bortezomib - administration & dosage (486) 486
drug resistance, neoplasm (484) 484
clinical trials (480) 480
dosage and administration (478) 478
immunology (476) 476
bortezomib - pharmacology (474) 474
protease inhibitors - pharmacology (473) 473
rituximab (472) 472
multiple myeloma - metabolism (469) 469
cyclophosphamide (461) 461
protease inhibitors - therapeutic use (459) 459
carfilzomib (457) 457
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11209) 11209
Chinese (220) 220
Japanese (135) 135
French (89) 89
German (87) 87
Russian (49) 49
Spanish (43) 43
Polish (42) 42
Czech (40) 40
Korean (18) 18
Hungarian (14) 14
Turkish (6) 6
Italian (4) 4
Slovenian (4) 4
Portuguese (3) 3
Danish (2) 2
Croatian (1) 1
Dutch (1) 1
Persian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2016, Volume 113, Issue 46, pp. 13162 - 13167
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2016, Volume 13, Issue 3, pp. 885 - 896
Abstract The development of resistance and subsequent metastasis makes prostate cancer a leading cause of cancer-related death among men. Hence,... 
Internal Medicine | Bortezomib | Zein nanoparticles | Prostate cancer | Vorinostat | MEDICINE, RESEARCH & EXPERIMENTAL | GRAPHENE OXIDE | LIPID NANOPARTICLES | ANDROGEN RECEPTOR | CELLS | DRUG-DELIVERY | NANOSCIENCE & NANOTECHNOLOGY | RELEASE | BREAST-CANCER | LIQUID-CRYSTALLINE NANOPARTICLES | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Histone Deacetylase Inhibitors - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Bortezomib - pharmacology | Drug Carriers - chemistry | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Histone Deacetylase Inhibitors - pharmacokinetics | Prostate - pathology | Neoplasm Metastasis - drug therapy | Hydroxamic Acids - administration & dosage | Prostate - drug effects | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Prostatic Neoplasms - drug therapy | Proteasome Inhibitors - pharmacokinetics | Prostatic Neoplasms - pathology | Proteasome Inhibitors - pharmacology | Proteasome Inhibitors - administration & dosage | Nanoparticles - ultrastructure | Proteasome Inhibitors - therapeutic use | Hydroxamic Acids - pharmacokinetics | Drug Synergism | Particle Size | Cell Movement - drug effects | Animals | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - therapeutic use | Mice, Nude | Neoplasm Metastasis - pathology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Zein - chemistry | Histone Deacetylase Inhibitors - therapeutic use | Mice, Inbred BALB C | Bortezomib - pharmacokinetics | Proteins | Nanoparticles | Care and treatment | Metastasis | Cancer | Pharmacy | Drugstores | Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2017, Volume 57, Issue 9, pp. 1183 - 1193
Journal Article
Blood, ISSN 1528-0020, 2017, Volume 130, Issue 22, pp. 2392 - 2400
Journal Article
Revue du rhumatisme (Ed. française : 1993), ISSN 1169-8330, 2019, Volume 86, Issue 4, pp. 398 - 399
Journal Article